bioAffinity Technologies, Inc. [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20
	10-K	10-K	S-1/A
Revenue	0.0		1,415.3
Revenue growth		-100.0%
Cost of sales	0.0
Gross profit	0.0
Gross margin	90.3%

Operating expenses:
Research and development	1.1	1.0
Clinical development	0.1	0.1
General and administrative	2.7	1.1
Total operating expenses	4.0	2.2	2,604.4
Loss from operations	-4.0	-2.2	-2,604.4
Operating margin	-83511.5%

Other income (expense):
Interest income	0.0	0.0	1.1
Interest expense	-0.4	-0.5	-382.2
Gain on extinguishment of debt	0.2	0.2
Fair value adjustments on convertible notes payable	-1.9	0.7
Net loss before provision for income taxes	-8.2	-6.3
Income tax expense	0.0	0.0	2.8
Net loss	-8.2	-6.3	-7,268.7

Net loss per common share, basic	($1.81)	($2.36)	($2.72)
Net loss per common share, diluted	($1.81)	($2.36)	($2.72)

Weighted average common shares outstanding, basic	4.5	2.7
Weighted average common shares outstanding, diluted	4.5	2.7	2,674.9